Parbeer Grewal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Parbeer Grewal has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Alain Brassard
University of Alberta
2 shared publications- Maxime Barakat
Bausch Health Canada, Inc, Laval, QC, Canada
2 shared publications - Melinda Gooderham
Department of Dermatology Queens University Peterborough Ontario Canada
2 shared publications Perla Lansang
Division of Dermatology, Women's College Hospital, Toronto, ON, Canada
2 shared publications- Rami Abou Zeinab
Bausch Health Canada, Inc, Laval, QC, Canada
2 shared publications Ravina Sanghera
University of Alberta, Edmonton, AB, Canada
2 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Clinical Implications of Interleukin-17 as a Hepato-Dermal Link in Patients With Psoriasis and Concomitant Steatotic Liver Disease
Psoriasis is increasingly recognized as a systemic inflammatory disease with impacts beyond the skin and joints. Metabolic dysfunction-associated steatotic liver disease (MASLD) and excessive alcohol consumption are common in the psoriasis population, affecting up to two-thirds of patients. Interleukin-17 (IL-17) has been identified as a potential key pro-inflammatory link between psoriasis and MASLD. IL-17 levels have been positively correlated with progression of MASLD to more advanced forms of liver disease, including steatohepatitis, cirrhosis and hepatocellular carcinoma. Given the high prevalence of concurrent psoriasis and liver disease, dermatologists should have an elevated index of suspicion of MASLD in patients with psoriasis, particularly those with concomitant metabolic risk factors and/or excessive alcohol consumption. Using 3 parameters, the Fibrosis-4 index is a validated, non-invasive screening tool that can be implemented in clinical practice. With the wide variety of therapeutics available to treat psoriasis, practitioners should be mindful of systemic agents carrying potential hepatotoxic adverse effects and could consider instead implementation of advanced therapies that have neutral or potentially beneficial effects on the liver. There is emerging data, pending larger prospective confirmatory studies, that support consideration of IL-17 inhibitors as a reasonable option in appropriate patients with or at risk of MASLD.
- 14 October 2026
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
Open AccessClinical Implications of Interleukin-17 as a Hepato-Dermal Link in Patients With Psoriasis and Concomitant Steatotic Liver Disease
Psoriasis is increasingly recognized as a systemic inflammatory disease with impacts beyond the skin and joints. Metabolic dysfunction-associated steatotic liver disease (MASLD) and excessive alcohol consumption are common in the psoriasis population, affecting up to two-thirds of patients. Interleukin-17 (IL-17) has been identified as a potential key pro-inflammatory link between psoriasis and MASLD. IL-17 levels have been positively correlated with progression of MASLD to more advanced forms of liver disease, including steatohepatitis, cirrhosis and hepatocellular carcinoma. Given the high prevalence of concurrent psoriasis and liver disease, dermatologists should have an elevated index of suspicion of MASLD in patients with psoriasis, particularly those with concomitant metabolic risk factors and/or excessive alcohol consumption. Using 3 parameters, the Fibrosis-4 index is a validated, non-invasive screening tool that can be implemented in clinical practice. With the wide variety of therapeutics available to treat psoriasis, practitioners should be mindful of systemic agents carrying potential hepatotoxic adverse effects and could consider instead implementation of advanced therapies that have neutral or potentially beneficial effects on the liver. There is emerging data, pending larger prospective confirmatory studies, that support consideration of IL-17 inhibitors as a reasonable option in appropriate patients with or at risk of MASLD.
- Open Access
- 11 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (10) , 5195-5214
Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study
- 11 September 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (10) , 5195-5214
Open AccessReal-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study
- Open Access
- 16 April 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (6) , 2931-2946
Canadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS)
Treat-to-target (T2T) strategies have been proposed to support decision-making in chronic plaque psoriasis care, but their use in Canadian clinical practice has not been well studied. This retrospective chart review examined how Canadian T2T criteria are applied for adult patients with moderate-to-severe plaque psoriasis and whether treatment decisions reflect treatment target achievement in clinical practice. Charts from 438 adults who initiated or modified biologic therapy and completed two visits 3-8 months apart were included. Treatment target achievement at visit 2 was assessed using predefined major and minor criteria, which included Psoriasis Area and Severity Index (PASI), body surface area (BSA), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) outcome measures. Of the 438 patients, 321 (73.3%) met the treatment target and 98.4% of these continued their current biologic therapy. Among the 117 patients who did not meet the treatment target, 48.7% of remained on their current biologic therapy. Treatment target achievement was associated with lower PASI, BSA, PGA, and DLQI scores. DLQI influenced treatment modification even when treatment targets were unmet. Switching between interleukin (IL)-17 and IL-23 inhibitors was the most frequent treatment modification strategy. Findings support the clinical value of Canadian T2T criteria, while highlighting the importance of shared decision-making. Many patients who did not meet treatment targets remained on their current biologic therapy, emphasizing the role of patient input, quality of life, and physician judgment. These results reinforce the importance of balancing treatment targets with individualized care in real-world plaque psoriasis management.
- 16 April 2026
- Published by Springer Nature in Dermatology and Therapy
- Vol. 16 (6) , 2931-2946
Open AccessCanadian Treat-to-Target Practice Survey of Real-World Interventions and Strategies in Psoriasis (CAN TARGET PSORIASIS)
Treat-to-target (T2T) strategies have been proposed to support decision-making in chronic plaque psoriasis care, but their use in Canadian clinical practice has not been well studied. This retrospective chart review examined how Canadian T2T criteria are applied for adult patients with moderate-to-severe plaque psoriasis and whether treatment decisions reflect treatment target achievement in clinical practice. Charts from 438 adults who initiated or modified biologic therapy and completed two visits 3-8 months apart were included. Treatment target achievement at visit 2 was assessed using predefined major and minor criteria, which included Psoriasis Area and Severity Index (PASI), body surface area (BSA), Physician Global Assessment (PGA), and Dermatology Life Quality Index (DLQI) outcome measures. Of the 438 patients, 321 (73.3%) met the treatment target and 98.4% of these continued their current biologic therapy. Among the 117 patients who did not meet the treatment target, 48.7% of remained on their current biologic therapy. Treatment target achievement was associated with lower PASI, BSA, PGA, and DLQI scores. DLQI influenced treatment modification even when treatment targets were unmet. Switching between interleukin (IL)-17 and IL-23 inhibitors was the most frequent treatment modification strategy. Findings support the clinical value of Canadian T2T criteria, while highlighting the importance of shared decision-making. Many patients who did not meet treatment targets remained on their current biologic therapy, emphasizing the role of patient input, quality of life, and physician judgment. These results reinforce the importance of balancing treatment targets with individualized care in real-world plaque psoriasis management.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 6874662
Management of Moderate‐to‐Severe Atopic Dermatitis With Systemic Medications: Review and Expert Commentary
Background: The systemic treatment of moderate‐to‐severe atopic dermatitis (AD) in adults has evolved significantly over the past decade in terms of treatment goals and therapeutic options. While many therapeutic options are endorsed by existing guidelines, newer therapies have been held to higher standards of efficacy and safety in clinical trials compared to “traditional” immunosuppressants used in AD. The robust evidence demonstrating the improved benefit‐to‐risk profiles of these newer medications implies that they should be prioritized, as they are more likely to enable patients to achieve modern treatment goals with less risk of adverse events. Objectives: To develop an evidence‐based algorithm for the systemic treatment of moderate‐to‐severe AD in adults, with a focus on the Canadian context, and prioritizing strength of evidence and safety over other factors such as cost and reimbursement. Methods: An expert panel of 6 Canadian dermatologists with expertise in AD identified randomized clinical trials and publications from prospective registries reporting on ≥ 100 adults taking systemic treatment for AD. The evidence supporting the various therapeutic options was summarized, evaluated, and synthesized into a draft evidence‐based algorithm for the systemic treatment of moderate‐to‐severe AD. Results and Implications: The evidence summaries were reviewed and discussed to create a new therapeutic algorithm, which was then refined through iterative review by all authors. This algorithm can provide evidence‐based support for decision‐making in the systemic treatment of moderate‐to‐severe AD in Canada and beyond.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 6874662
Open AccessManagement of Moderate‐to‐Severe Atopic Dermatitis With Systemic Medications: Review and Expert Commentary
Background: The systemic treatment of moderate‐to‐severe atopic dermatitis (AD) in adults has evolved significantly over the past decade in terms of treatment goals and therapeutic options. While many therapeutic options are endorsed by existing guidelines, newer therapies have been held to higher standards of efficacy and safety in clinical trials compared to “traditional” immunosuppressants used in AD. The robust evidence demonstrating the improved benefit‐to‐risk profiles of these newer medications implies that they should be prioritized, as they are more likely to enable patients to achieve modern treatment goals with less risk of adverse events. Objectives: To develop an evidence‐based algorithm for the systemic treatment of moderate‐to‐severe AD in adults, with a focus on the Canadian context, and prioritizing strength of evidence and safety over other factors such as cost and reimbursement. Methods: An expert panel of 6 Canadian dermatologists with expertise in AD identified randomized clinical trials and publications from prospective registries reporting on ≥ 100 adults taking systemic treatment for AD. The evidence supporting the various therapeutic options was summarized, evaluated, and synthesized into a draft evidence‐based algorithm for the systemic treatment of moderate‐to‐severe AD. Results and Implications: The evidence summaries were reviewed and discussed to create a new therapeutic algorithm, which was then refined through iterative review by all authors. This algorithm can provide evidence‐based support for decision‐making in the systemic treatment of moderate‐to‐severe AD in Canada and beyond.
- Open Access
- 22 July 2021
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 26 (1) , 71-78
A Clinician’s Guide to Topical Retinoids
Retinoids are defined as molecules that bind to and activate retinoic acid receptors to influence the proliferation and differentiation of cells. Topical retinoids have evolved over the past several decades, being used in multiple dermatological conditions. This review aims to differentiate between synthetic and natural retinoids, discuss the pharmacology behind topical retinoids, highlight clinical applications, and categorize all the commercially available agents, including combination products. Understanding retinoid affinities for unique receptor subtypes can impact clinical decisions, resulting in optimizing treatment and enhancing patient adherence.
- 22 July 2021
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 26 (1) , 71-78
Open AccessA Clinician’s Guide to Topical Retinoids
Retinoids are defined as molecules that bind to and activate retinoic acid receptors to influence the proliferation and differentiation of cells. Topical retinoids have evolved over the past several decades, being used in multiple dermatological conditions. This review aims to differentiate between synthetic and natural retinoids, discuss the pharmacology behind topical retinoids, highlight clinical applications, and categorize all the commercially available agents, including combination products. Understanding retinoid affinities for unique receptor subtypes can impact clinical decisions, resulting in optimizing treatment and enhancing patient adherence.
- 5 June 2020
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 24 (1_suppl) , 3S-14S
Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper
Background: Plaque psoriasis (PsO) is a chronic inflammatory disease that often presents at peak reproductive age in women of child-bearing potential (WOCBP). With the emergence of biologic therapies to treat PsO, guidance on disease management in WOCBP is needed to inform treatment decisions before, during, and after pregnancy. Objectives: To develop a practical, up-to-date consensus document, based on available evidence and expert opinion where evidence was lacking, in order to guide both Canadian and international clinicians treating PsO in WOCBP. Methods: A panel of 9 Canadian dermatologists with extensive clinical experience managing PsO reviewed the relevant literature from the past 25 years in 3 key domains: overview of PsO in WOCBP and clinical considerations, treatment considerations, and postpartum considerations. The structured literature search focused on WOCBP treated with TNF-alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), IL-12/23 inhibitors (ustekinumab), and IL-17 inhibitors (brodalumab, ixekizumab, secukinumab). This literature review, along with clinical expertise and opinion, was used to develop concise and clinically relevant consensus statements to guide practical management of PsO in WOCBP. Experts voted on the statements using a modified Delphi process and prespecified agreement cut-off of 75%. Results and implications: After review, discussion, and voting on 19 draft consensus statements at an in-person meeting and remotely, 12 consensus statements were approved by the expert panel. The statements presented here will guide healthcare providers in practical disease management using biologic therapies for the treatment of PsO in WOCBP.
- 5 June 2020
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 24 (1_suppl) , 3S-14S
Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper
Background: Plaque psoriasis (PsO) is a chronic inflammatory disease that often presents at peak reproductive age in women of child-bearing potential (WOCBP). With the emergence of biologic therapies to treat PsO, guidance on disease management in WOCBP is needed to inform treatment decisions before, during, and after pregnancy. Objectives: To develop a practical, up-to-date consensus document, based on available evidence and expert opinion where evidence was lacking, in order to guide both Canadian and international clinicians treating PsO in WOCBP. Methods: A panel of 9 Canadian dermatologists with extensive clinical experience managing PsO reviewed the relevant literature from the past 25 years in 3 key domains: overview of PsO in WOCBP and clinical considerations, treatment considerations, and postpartum considerations. The structured literature search focused on WOCBP treated with TNF-alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab), IL-12/23 inhibitors (ustekinumab), and IL-17 inhibitors (brodalumab, ixekizumab, secukinumab). This literature review, along with clinical expertise and opinion, was used to develop concise and clinically relevant consensus statements to guide practical management of PsO in WOCBP. Experts voted on the statements using a modified Delphi process and prespecified agreement cut-off of 75%. Results and implications: After review, discussion, and voting on 19 draft consensus statements at an in-person meeting and remotely, 12 consensus statements were approved by the expert panel. The statements presented here will guide healthcare providers in practical disease management using biologic therapies for the treatment of PsO in WOCBP.
- 5 March 2020
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 24 (3) , 292-296
Off-Label Therapeutic Potential of Crisaborole
Crisaborole, a topical phosphodiesterase-4 inhibitor, was recently approved in 2016 for the treatment of mild to moderate atopic dermatitis in adults and children greater than 2 years of age. Since that time, several case reports and a small randomized controlled trial have been published regarding the off-label use of crisaborole for the treatment of other inflammatory dermatologic disorders. This paper reviews the current, albeit limited, evidence for off-label use of crisaborole for psoriasis, seborrheic dermatitis, vitiligo, and inflammatory linear verrucous epidermal nevus. Additional potential therapeutic uses for crisaborole are also postulated, based on its mechanism of action. Future studies are required to elucidate the full therapeutic potential of crisaborole; however, it is a welcome addition to the current nonsteroid topical treatments for inflammatory dermatologic disease.
- 5 March 2020
- Published by SAGE Publications in Journal of Cutaneous Medicine and Surgery
- Vol. 24 (3) , 292-296
Off-Label Therapeutic Potential of Crisaborole
Crisaborole, a topical phosphodiesterase-4 inhibitor, was recently approved in 2016 for the treatment of mild to moderate atopic dermatitis in adults and children greater than 2 years of age. Since that time, several case reports and a small randomized controlled trial have been published regarding the off-label use of crisaborole for the treatment of other inflammatory dermatologic disorders. This paper reviews the current, albeit limited, evidence for off-label use of crisaborole for psoriasis, seborrheic dermatitis, vitiligo, and inflammatory linear verrucous epidermal nevus. Additional potential therapeutic uses for crisaborole are also postulated, based on its mechanism of action. Future studies are required to elucidate the full therapeutic potential of crisaborole; however, it is a welcome addition to the current nonsteroid topical treatments for inflammatory dermatologic disease.
- 23 July 2013
- Published by Springer Nature
- p. 119-125
Psoriasis and Psoriatic Arthritis
- 23 July 2013
- Published by Springer Nature
- p. 127-132
Inflammatory Bowel-Associated Spondyloarthropathy